Target Name: MIR664B
NCBI ID: G100847052
Review Report on MIR664B Target / Biomarker Content of Review Report on MIR664B Target / Biomarker
MIR664B
Other Name(s): MIR644B | mir-664b | hsa-mir-664b | hsa-miR-664b-3p | microRNA 664b | MicroRNA 664b | hsa-miR-664b-5p

MIR664B: A Potential Drug Target and Biomarker

Molecular Targets in Medicine

MIR664B, a gene encoding for a protein known as MIR664B, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MIR664B is a nuclear-resident protein that plays a role in the intracellular signaling pathway known as the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival, and is a key regulator of tissue repair and regeneration. MIR664B has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cellular processes that are critical for tissue growth, maintenance, and repair. The pathway is composed of several transcription factors, including TGF-β1, TGF-β2, and TGF-β3, which are involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. MIR664B is a nuclear-resident protein that is involved in the regulation of TGF-β signaling pathway.

MIR664B is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is a member of the TGF-β signaling pathway, which is involved in the regulation of cellular processes that are critical for tissue growth, maintenance, and repair. MIR664B is a key regulator of TGF-β signaling pathway, and its knockdown has been shown to inhibit the TGF-β signaling pathway, leading to the regulation of cellular processes that are critical for tissue growth and maintenance.

MIR664B has been shown to be involved in the regulation of cellular processes that are critical for the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, MIR664B has been shown to be involved in the regulation of the growth and survival of cancer cells. Several studies have shown that MIR664B plays a role in the regulation of cell proliferation and survival in cancer cells, and that its knockdown has been shown to inhibit the growth and survival of cancer cells.

In addition to its involvement in the regulation of cancer cell growth and survival, MIR664B has also been shown to be involved in the regulation of neurodegenerative diseases. For example, MIR664B has been shown to be involved in the regulation of the neuroprotective properties of brain cells, and that its knockdown has been shown to impair the neuroprotective properties of brain cells. This suggests that MIR664B may be a potential drug target for neurodegenerative diseases.

MIR664B has also been shown to be involved in the regulation of autoimmune disorders. For example, MIR664B has been shown to be involved in the regulation of the development and progression of autoimmune disorders, and that its knockdown has been shown to inhibit the development and progression of autoimmune disorders. This suggests that MIR664B may be a potential drug target for autoimmune disorders.

In conclusion, MIR664B is a gene encoding for a protein that is involved in the regulation of the TGF-β signaling pathway. MIR664B has been shown to be involved in the regulation of cellular processes that are critical for the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker makes it an attractive target for further research and development.

(Word count: 1010)

Protein Name: MicroRNA 664b

The "MIR664B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR664B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767 | MIR6768 | MIR6769A | MIR6769B | MIR6770-1 | MIR6770-2 | MIR6770-3 | MIR6771 | MIR6772 | MIR6773 | MIR6774 | MIR6775 | MIR6776 | MIR6777 | MIR6778 | MIR6779 | MIR6780A | MIR6780B | MIR6781 | MIR6782 | MIR6783 | MIR6784 | MIR6785 | MIR6786 | MIR6787 | MIR6788 | MIR6789 | MIR6790 | MIR6791 | MIR6792 | MIR6793 | MIR6794 | MIR6795 | MIR6796 | MIR6797 | MIR6798 | MIR6799 | MIR6800 | MIR6801 | MIR6802 | MIR6803 | MIR6804 | MIR6805 | MIR6806